Media coverage about Ocular Therapeutix (NASDAQ:OCUL) has been trending positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocular Therapeutix earned a news sentiment score of 0.26 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.3641187508396 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s analysis:
- Ocular Therapeutix, Inc. (OCUL) Upgraded to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Which Way Traders Signposts: Ocular Therapeutix, Inc., (NASDAQ: OCUL), Scorpio Bulkers Inc., (NYSE: SALT … – Stocks In The News (press release) (tradingnewsnow.com)
- Edited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMT (finance.yahoo.com)
- Ocular Therapeutix, Inc. (OCUL) Given Buy Rating at HC Wainwright (americanbankingnews.com)
- Critical Contrast: Ocular Therapeutix (OCUL) & Its Peers (americanbankingnews.com)
A number of equities research analysts recently commented on OCUL shares. Guggenheim started coverage on Ocular Therapeutix in a research report on Monday, October 23rd. They issued a “buy” rating and a $12.00 target price on the stock. Zacks Investment Research lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. BTIG Research reiterated a “neutral” rating on shares of Ocular Therapeutix in a research report on Monday, July 17th. ValuEngine lowered Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 21st. Finally, HC Wainwright initiated coverage on Ocular Therapeutix in a research report on Wednesday, July 26th. They issued a “buy” rating and a $10.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $22.29.
Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.54). Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The business had revenue of $523.00 million for the quarter, compared to analyst estimates of $0.52 million. During the same quarter in the prior year, the firm posted ($0.39) EPS. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. analysts predict that Ocular Therapeutix will post -2.35 EPS for the current year.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.